BridgeBio Pharma BBIO) stock received a Perform rating from Oppenheimer on market challenges to its late-stage assets acoramidis and infigratinib. Read more here.
The successful commercialization of acoramidis could establish BridgeBio as a key player in the ATTR-CM market, significantly improving its path to profitability. BridgeBio's valuation relies on the ...
During the meeting Hyderabad CP explained to the gathering about the difficulties faced by not only various government departments but also the general public due to the uncontrolled use of DJ Systems ...